


PRODUCT INFORMATION



L-826,266

Item No. 18538

CAS Registry No.: 244101-03-9
Formal Name: (2E)-N-[(5-bromo-2-methoxyphenyl)sulfonyl]-3-[5-chloro-2-(2-naphthalenylmethyl)phenyl]-2-propenamamide
MF: C₂₇H₂₁BrClNO₄S
FW: 570.9
Purity: ≥98%
UV/Vis.: λ_{max}: 222 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

L-826,266 is supplied as a crystalline solid. A stock solution may be made by dissolving the L-826,266 in the solvent of choice. L-826,266 is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of L-826,266 in these solvents is approximately 10 and 20 mg/ml, respectively.

Description

L-826,266 is a potent and selective competitive antagonist of the prostaglandin E₂ receptor subtype EP₃ (K_i = 0.8 nM).¹ It also binds to the EP₄ receptor (K_i = 715 nM) but does not bind to EP₁ or EP₂ receptors up to a concentration of 5,000 nM. L-826,266 inhibits vasoconstriction induced by the EP₃ agonist sulprostone (Item No. 14765) in a concentration-dependent manner (EC₅₀s = 0.45-24.5 μM in isolated human pulmonary arteries).² It also inhibits sulprostone-induced norepinephrine and serotonin release in rat cortex and norepinephrine release in rat vas deferens (pA₂s = 7.56, 7.67, and 7.87, respectively).³

References

1. Juteau, H., Gareau, Y., Labelle, M., *et al.* Structure-activity relationship of cinnamic acylsulfonamide analogues on the human EP₃ prostanoid receptor. *Bioorg. Med. Chem.* **9(8)**, 1977-1984 (2001).
2. Kozłowska, H., Baranowska-Kuczko, M., Schlicker, E., *et al.* EP₃ receptor-mediated contraction of human pulmonary arteries and inhibition of neurogenic tachycardia in pithed rats. *Pharmacol. Rep.* **64(6)**, 1526-1536 (2012).
3. Günther, J., Schulte, K., Wenzel, D., *et al.* Prostaglandins of the E series inhibit monoamine release via EP₃ receptors: Proof with the competitive EP₃ receptor antagonist L-826,266. *Naunyn Schmiedebergs Arch. Pharmacol.* **381(1)**, 21-31 (2010).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/22/2018

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM